| Audience | Patients, caregivers, clinicians, and cannabis-science readers interested in short-term pain after photorefractive keratectomy |
| Primary Topic | oral CBD compared with codeine-acetaminophen after photorefractive keratectomy |
| Source | Read the full source |
CBD Versus Codeine After Laser Eye Surgery: What a 35-Person Trial Found
A randomized crossover trial in 35 adults found no significant difference in reported pain between oral CBD and codeine-acetaminophen after photorefractive keratectomy. Recovery measures were also similar, while mild sensorium changes appeared with first CBD exposure. The result is clinically interesting, but it does not establish broad equivalence or an opioid-sparing standard.
| Study Type | Prospective, randomized, crossover, self-controlled clinical trial |
| Population | 35 adults undergoing bilateral sequential photorefractive keratectomy |
| Intervention | Low-THC oral CBD, 50 mg twice daily |
| Comparator | Codeine-acetaminophen 30 mg/300 mg every 4 hours |
| Sequence | Each participant received one regimen for one eye procedure and the other regimen for the contralateral eye in randomized order |
| Primary Outcomes | Pain and uncorrected visual acuity at postoperative month 3 |
| Pain Result | Mean and maximum pain ratings did not differ significantly; p = 0.538 |
| Vision Result | Visual acuity improved by month 3 with no treatment-related difference; p = 0.928 |
| Safety Signal | Sensorium scores were higher when CBD was used for the first eye, suggesting a first-exposure effect; p = 0.035 |
| Major Limitation | Small single-practice study with sequential procedures; the abstract does not report blinding, a noninferiority margin, or confidence intervals for the pain comparison |
| Journal | Journal of Cataract & Refractive Surgery |
| Published Online | July 29, 2026 |
| PMID | 42524865 |
| DOI | 10.1097/j.jcrs.0000000000002030 |
Thirty-five adults underwent sequential PRK procedures in both eyes. In randomized order, each participant received oral CBD after one eye procedure and codeine-acetaminophen after the other.
The CBD regimen was 50 mg twice daily. The comparator was codeine 30 mg with acetaminophen 300 mg every four hours. Participants recorded pain and symptoms, and investigators assessed visual and quality-of-life outcomes.
Pain peaked on postoperative day 2 with both regimens. The abstract reports no statistically significant difference in mean or maximum pain ratings between treatments.
Visual acuity improved by month 3 without a treatment-related difference. Other symptoms and patient-reported outcomes were described as equivalent, although the abstract provides limited numerical detail.
A nonsignificant superiority test does not by itself prove that two treatments are noninferior or clinically equivalent. A formal noninferiority conclusion ordinarily requires a prespecified margin and confidence interval showing that the difference stays within that margin.
Those details are not reported in the PubMed abstract. Until the full statistical plan is reviewed, the safest description is that this small study detected no significant pain-score difference.
Sensorium scores were significantly higher when CBD was used after the first eye procedure, but not when it followed the second procedure. The authors interpreted this as a first-exposure effect.
That finding deserves practical attention because even mild subjective changes can matter for driving, work, medication combinations, and postoperative instructions.
The trial did not establish that CBD reduces opioid exposure across surgical care, works in other acute-pain settings, or matches non-opioid standards such as acetaminophen and NSAID-based regimens.
Larger blinded trials should report rescue medication, adverse events, clinically meaningful pain differences, noninferiority margins, confidence intervals, and patient-level preferences.
Postoperative opioid reduction is an important goal, but the relevant comparison is not simply CBD versus an opioid. Modern pain care often uses procedure-specific combinations of local therapy, acetaminophen, anti-inflammatory medication when appropriate, and limited rescue opioids.
CBD also varies across products. A studied low-THC oral formulation cannot validate untested retail products with different concentrations, contaminants, absorption, or labeling accuracy.
I find this trial worth attention because it asks a direct clinical question in humans and uses each participant as their own comparator. That is more useful than an anecdote or a mechanistic claim.
The responsible conclusion is still narrower than the abstract’s strongest language. Similar observed pain scores in 35 people are a signal for a larger trial, not a new postoperative standard.
How to Interpret This Oral Cbd Compared With Codeine-Acetaminophen After Photorefractive Keratectomy Evidence Without Overstating It
A useful evidence report should let the signal breathe without inflating it.
The right question is not whether the paper is positive or negative, but what kind of decision it can responsibly support.
A Four-Step Reading Frame
Evidence type
Start by identifying whether the paper is a randomized trial, review, meta-analysis, observational study, or protocol.
Population
Ask whether the studied population matches the patient or clinical scenario involving short-term pain after photorefractive keratectomy.
Outcome meaning
Look at what actually changed, how it was measured, and whether the change would matter in daily life.
Safety and uncertainty
Read limitations and adverse effects as part of the result, not as a footnote.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.
A Signal Worth Discussing, Not Self-Prescribing
For patients interested in oral CBD compared with codeine-acetaminophen after photorefractive keratectomy, the paper creates a reasonable conversation starter but not a do-it-yourself treatment plan.
In this case, the key is to keep short-term pain after photorefractive keratectomy in view while avoiding claims the study did not test.
Useful Evidence With Practical Gaps
Clinicians can use the paper to discuss short-term pain after photorefractive keratectomy, but the evidence still leaves product, dose, monitoring, and patient-selection questions open.
In this case, the key is to keep short-term pain after photorefractive keratectomy in view while avoiding claims the study did not test.
Small Evidence Bases Can Look Larger in Review Form
Systematic reviews can make a field feel mature even when the underlying trials remain few, short, or heterogeneous.
In this case, the key is to keep short-term pain after photorefractive keratectomy in view while avoiding claims the study did not test.
Outcome Measures Do Not Answer Every Bedside Question
The paper reports measurable outcomes, but patients also need information about durability, adverse effects, interactions, and real-world use.
In this case, the key is to keep short-term pain after photorefractive keratectomy in view while avoiding claims the study did not test.
A Step Forward, Not the Final Word
This paper advances the conversation by gathering available evidence, but it also highlights how much cannabinoid research still depends on small or uneven studies.
In this case, the key is to keep short-term pain after photorefractive keratectomy in view while avoiding claims the study did not test.
Monitoring Matters
If cannabinoids are considered clinically, monitoring should include symptom response, side effects, sedation or impairment, medication interactions, and patient goals.
In this case, the key is to keep short-term pain after photorefractive keratectomy in view while avoiding claims the study did not test.
What Better Evidence Would Need
Stronger trials should define formulation, dose, comparator, duration, responder profiles, and safety monitoring before broad claims are made.
In this case, the key is to keep short-term pain after photorefractive keratectomy in view while avoiding claims the study did not test.
Access Should Not Outrun Evidence Quality
Patients deserve access to careful information, but public messaging should not make early evidence sound settled.
In this case, the key is to keep short-term pain after photorefractive keratectomy in view while avoiding claims the study did not test.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
Does this study prove that oral CBD compared with codeine-acetaminophen after photorefractive keratectomy works?
No. It supports a clinically interesting signal, but proof requires larger, better-controlled, and more specific trials.
Is this enough evidence to change treatment on its own?
No. It can inform a clinical conversation, but it should not replace individualized medical judgment or established care.
Why does study design matter here?
Design affects how confidently readers can separate a true treatment effect from bias, placebo response, measurement choices, and patient selection.
What is the biggest limitation?
The biggest limitation is that the available studies are relatively small, heterogeneous, and not long enough to answer every practical safety question.
Does this apply to every cannabis or CBD product?
No. Products differ by cannabinoid content, dose, route, purity, and testing standards, so one paper cannot validate every product.
What should patients ask their clinician?
Patients should ask how the evidence relates to their own short-term pain after photorefractive keratectomy, medication list, risks, goals, and monitoring plan.
Are side effects still important if the findings are positive?
Yes. Benefit and risk have to be interpreted together, especially for sedation, impairment, interactions, and vulnerable populations.
Why include this as a full CED report?
The paper is recent, clinically relevant, and evidence-based enough to deserve careful standalone interpretation rather than a short mention.
What would stronger research add?
Stronger research would clarify formulation, dose, duration, responder profiles, active comparators, long-term outcomes, and safety monitoring.
What is the practical takeaway?
The practical takeaway is cautious interest: the signal is worth knowing, but the clinical decision still has to be individualized.
